StepStone Group Portfolio holdings
StepStone Group is a private markets firm that builds customized investment portfolios, monitors them and advises investors. Its business spans primary and secondary fund investments plus co-investments, across private equity, real estate, infrastructure, real assets and private debt. Its founders, Monte Brem and Thomas Keck, had earlier made private equity investments at Pacific Corporate Group, as president and managing director respectively. StepStone went public on the Nasdaq in September 2020. The firm serves institutional investors and sponsors worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Entrada Therapeutics
TRDA
|
+$1.6M |
| 2 |
Forge Global Holdings
FRGE
|
+$1.04M |
| 3 |
Vacasa, Inc. Class A Common Stock
VCSA
|
+$676K |
| 4 |
Procore
PCOR
|
+$426K |
| 5 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$186K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xometry
XMTR
|
+$100M |
| 2 |
Planet Labs
PL
|
+$3.6M |
| 3 |
HashiCorp, Inc. Class A Common Stock
HCP
|
+$2.03M |
| 4 |
10x Genomics
TXG
|
+$153K |
| 5 |
Advanced Drainage Systems
WMS
|
+$122K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 43% |
| 2 | Technology | 29.67% |
| 3 | Healthcare | 14.5% |
| 4 | Industrials | 8.51% |
| 5 | Communication Services | 2.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Dun & Bradstreet
DNB
| $273M | 38.84% |
22,042,226
| – | – |
2021 Q4
3 quarters
|
|
|
USER
2
DELISTED
UserTesting, Inc.
USER
| $97.5M | 13.86% |
24,868,471
| – | – |
2021 Q4
3 quarters
|
|
3
DELISTED
WalkMe Ltd. Ordinary Shares
WKME
| $88.1M | 12.53% |
10,366,855
| – | – |
2021 Q3
4 quarters
|
|
4
Rocket Lab Corp
RKLB
$33.9B
| $50M | 7.1% |
12,273,414
-20,147
| -0.2% | -$99.4K |
2021 Q3
4 quarters
|
|
5
DELISTED
NeueHealth
NEUE
| $43.8M | 6.22% |
521,066
| – | – |
2021 Q3
4 quarters
|
|
6
UiPath
PATH
$6.78B
| $22.5M | 3.2% |
1,786,527
| – | – |
2021 Q3
4 quarters
|
|
7
DELISTED
MoneyLion Inc.
ML
| $21.7M | 3.09% |
813,661
| – | – |
2021 Q3
4 quarters
|
|
|
NGM
8
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $20.6M | 2.93% |
1,573,357
| – | – |
2021 Q3
4 quarters
|
|
9
Roblox
RBLX
$35.3B
| $16.8M | 2.39% |
469,052
+881
| +0.2% | +$36.4K |
2021 Q3
4 quarters
|
|
|
10
Entrada Therapeutics
TRDA
$191M
| $12M | 1.71% |
761,277
+126,318
| +20% | +$1.6M |
2021 Q4
3 quarters
|
|
11
DELISTED
HilleVax
HLVX
| $11.6M | 1.64% |
676,567
| – | – |
2022 Q2
1 quarter
|
|
|
12
DELISTED
Vacasa, Inc. Class A Common Stock
VCSA
| $9.6M | 1.37% |
157,020
+9,759
| +7% | +$676K |
2021 Q4
3 quarters
|
|
13
DELISTED
Rover Group, Inc. Class A Common Stock
ROVR
| $9.5M | 1.35% |
2,849,340
| – | – |
2021 Q3
4 quarters
|
|
|
IMGO
14
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $7.87M | 1.12% |
522,987
| – | – |
2021 Q3
4 quarters
|
|
15
DELISTED
Doma Holdings, Inc.
DOMA
| $6.55M | 0.93% |
595,179
| – | – |
2021 Q3
4 quarters
|
|
16
Phathom Pharmaceuticals
PHAT
$427M
| $4.68M | 0.67% |
422,085
| – | – |
2021 Q3
4 quarters
|
|
17
Grove Collaborative
GROV
$46.5M
| $3.91M | 0.56% |
348,813
| – | – |
2022 Q2
1 quarter
|
|
18
Tenaya Therapeutics
TNYA
$82.1M
| $1.34M | 0.19% |
462,163
| – | – |
2021 Q3
4 quarters
|
|
19
TaoWeave Inc
TWAV
$5.04M
| $554K | 0.08% |
6,154
| – | – |
2021 Q3
4 quarters
|
|
|
20
DELISTED
Forge Global Holdings
FRGE
| $396K | 0.06% |
+15,080
| New | +$1.04M |
2022 Q3
0 quarters
|
|
|
21
Procore
PCOR
$11.4B
| $392K | 0.06% |
+7,930
| New | +$426K |
2022 Q3
0 quarters
|
|
|
22
Xometry
XMTR
$6.63B
| $227K | 0.03% |
3,990
-2,144,755
| -100% | -$100M |
2021 Q3
4 quarters
|
|
|
KDNY
23
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $182K | 0.03% |
+9,277
| New | +$186K |
2022 Q3
0 quarters
|
|
24
DELISTED
Couchbase
BASE
| $68K | 0.01% |
+4,773
| New | +$77.2K |
2022 Q3
0 quarters
|
|
25
DELISTED
ACV Auctions
ACVA
| $63K | 0.01% |
+8,816
| New | +$70K |
2022 Q3
0 quarters
|
|
Similar funds
StepStone Group's Q3 2022 Portfolio in Review
As of Q3 2022, StepStone Group held 36 positions worth $703M, down 25% from $935M the previous quarter. Its ten largest holdings account for 92% of the portfolio.
StepStone Group withdrew a net $102M in Q3 2022, closing 6 positions and reducing 2 holdings. Its most notable exit was Planet Labs, an estimated $3.6M position sold in full.
By sector, the portfolio is most concentrated in Financials at 43% of assets, up from 41% a quarter earlier, followed by Technology and Healthcare.
Against the trend, StepStone Group opened a new position in Forge Global Holdings worth $396K.
- StepStone Group's largest Q3 2022 buy was Forge Global Holdings: 15,080 shares worth $396K.
- StepStone Group added most to Entrada Therapeutics in Q3 2022, an estimated $1.6M increase.
- StepStone Group's biggest Q3 2022 reduction was Xometry, cutting an estimated $100M.
- StepStone Group fully exited Planet Labs in Q3 2022, selling an estimated $3.6M.
- StepStone Group's ten largest holdings make up 92% of its $703M portfolio in Q3 2022.
- StepStone Group opened 9 new positions and closed 6 in Q3 2022.
- StepStone Group's portfolio value fell 25% quarter-over-quarter to $703M.
Based on StepStone Group's 13F filing for Q3 2022, filed 14 Nov 2022.